PCM
BNGO icon

Prelude Capital Management’s Bionano Genomics BNGO Stock Holding History

Prelude Capital Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17
Closed -$14.6K – 1195
2022
Q4 		$14.6K Buy
+17
New +$21.4K ﹤0.01% 1188

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Prelude Capital Management's BNGO Position: Q1 2023 in Review

Prelude Capital Management sold out of Bionano Genomics (BNGO) in Q1 2023, closing a stake of 17 shares — an estimated $14.6K sold.

Prelude Capital Management first reported a position in BNGO in Q4 2022 and held it in 1 quarter. The position peaked at $14.6K in Q4 2022. 126 funds tracked by Wall St. Rank hold BNGO as of Q1 2023.

  • Prelude Capital Management reported no remaining Bionano Genomics position as of Q1 2023 after selling out during the quarter.
  • Prelude Capital Management sold 17 Bionano Genomics shares in Q1 2023, an estimated $14.6K.
  • Prelude Capital Management first reported a position in Bionano Genomics in Q4 2022 and held it in 1 quarter.
  • Prelude Capital Management's Bionano Genomics position peaked at $14.6K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.